Codiak Biosciences Profit Margin

The latest profit margin for CDAK is -87.08% as of September 2022. That compares with -425.26% in the prior-year period — up 79.5% year over year. That is below the Healthcare sector average of 14.41%. Investors often review this figure alongside Codiak Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, CDAK's profit margin moved from -425.26% to -87.08% — a 79.5% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Codiak Biosciences's valuation or profitability profile.

Against Healthcare companies, CDAK currently prints -87.08% for profit margin, while the sector average sits near 14.41%. That is roughly 704.1% below the sector mean. Large gaps often invite a closer look at Codiak Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Codiak Biosciences converts resources into returns. At -87.08%, CDAK may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -425.26% in the prior-year period — up 79.5% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting CDAK's profit margin (-87.08%), review year-over-year change from -425.26%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.